. Author manuscript; available in PMC: 2023 Sep 1.

Published in final edited form as: Pediatr Crit Care Med. 2022 Jun 10;23(9):687–697. doi: 10.1097/PCC.0000000000003009

Table 3.

Estimated Effect of Early Corticosteroid Therapy on Primary Outcomes

	Adjusted odds ratio (95% CI)	Adjusted effect (95% CI)	P-value
Outcomes (N=352)
Vasoactive-inotropic support-free days		0.72 (−0.85, 2.29)	0.370
Duration of vasoactive-inotropic support^*		−0.37 (−1.47, 0.72)	0.503
Survival to Month 1 without new morbidity^1,2	1.37 (0.83, 2.28)		0.218
Survival to Month 1	1.46 (0.62, 3.60)		0.387
New morbidity^*	0.70 (0.39, 1.23)		0.218
Outcomes (HRQL cohort, N=229)
PSD³ of HRQL or mortality at Month 1	0.70 (0.40, 1.23)		0.212
Mortality at Month 1	0.63 (0.25, 1.50)		0.298
PSD of HRQL among Month-1 survivors	0.74 (0.38, 1.41)		0.360

Models were weighted using stabilized inverse probability of treatment weights. Additionally, all models control for PRISM III and Site I.

Among Month-1 survivors.

Month 1 refers to 21–42 calendar days following the hospital admission.

There were four subjects missing FSS at Day 28 or hospital discharge. New morbidity was defined as a worsening in Functional Status Score (FSS) by 3 or more points from baseline to hospital discharge or Day 28, whichever came first.

PSD, persistent, severe deterioration of HRQL below baseline, specifically, HRQL scores (PedsQL™ or FSII-R) persisting > 25% below the baseline HRQL.